Artivion (NYSE:AORT) SVP Sells 11,480 Shares of Stock

Artivion, Inc. (NYSE:AORT) SVP Andrew Green sold 11,480 shares of the stock in a transaction on Thursday, September 10th. The stock was sold at an average price of $24.97, for a total value of $286,655.60. Following the transaction, the senior vice president directly owned 40,160 shares in the company, valued at $1,002,795.20. The trade was a 22.23% decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink.

Artivion Stock Up 1.9%

NYSE:AORT traded up $0.48 during mid-day trading on Friday, reaching $25.13. The company’s stock had a trading volume of 547,889 shares, compared to its average volume of 599,139. The company has a quick ratio of 2.51, a current ratio of 3.47 and a debt-to-equity ratio of 0.82. Artivion, Inc. has a 1 year low of $19.16 and a 1 year high of $48.25. The stock has a fifty day moving average of $26.25 and a 200-day moving average of $28.81. The firm has a market capitalization of $1.23 billion, a PE ratio of -358.92 and a beta of 1.25.

Artivion (NYSE:AORT) last announced its quarterly earnings results on Thursday, August 6th. The company reported $0.13 earnings per share for the quarter. Artivion had a negative net margin of 0.67% and a positive return on equity of 6.07%. The firm had revenue of $125.76 million during the quarter, compared to analysts’ expectations of $119.99 million. Equities research analysts forecast that Artivion, Inc. will post 0.45 earnings per share for the current year.

Wall Street Analysts Forecast Growth

AORT has been the subject of a number of analyst reports. Weiss Ratings cut Artivion from a “sell (d+)” rating to a “sell (d-)” rating in a research note on Tuesday, August 11th. Needham & Company LLC reiterated a “buy” rating and issued a $44.00 target price on shares of Artivion in a research note on Monday, July 20th. Canaccord Genuity Group boosted their target price on shares of Artivion from $39.00 to $40.00 and gave the stock a “buy” rating in a report on Tuesday, August 18th. Citigroup reissued a “market outperform” rating on shares of Artivion in a research report on Tuesday, July 21st. Finally, Wall Street Zen cut shares of Artivion from a “hold” rating to a “sell” rating in a report on Saturday, August 15th. Seven equities research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average price target of $44.83.

Institutional Trading of Artivion

Institutional investors have recently made changes to their positions in the business. Caitong International Asset Management Co. Ltd purchased a new position in Artivion during the 3rd quarter worth $27,000. Rockefeller Capital Management L.P. raised its stake in Artivion by 150.0% in the fourth quarter. Rockefeller Capital Management L.P. now owns 665 shares of the company’s stock valued at $30,000 after buying an additional 399 shares during the last quarter. Larson Financial Group LLC boosted its holdings in Artivion by 148.5% in the fourth quarter. Larson Financial Group LLC now owns 942 shares of the company’s stock worth $43,000 after acquiring an additional 563 shares in the last quarter. Smartleaf Asset Management LLC grew its stake in shares of Artivion by 47.7% during the second quarter. Smartleaf Asset Management LLC now owns 1,667 shares of the company’s stock worth $52,000 after acquiring an additional 538 shares during the last quarter. Finally, Kemnay Advisory Services Inc. acquired a new position in shares of Artivion during the fourth quarter valued at about $79,000. Institutional investors and hedge funds own 86.37% of the company’s stock.

About Artivion

Artivion, Inc (NYSE: AORT) is a global medical technology company that develops, manufactures and markets implantable tissue products and surgical devices for cardiac and vascular surgery. The company’s portfolio includes biologic implants derived from human and animal tissue, such as allografts and xenografts, as well as synthetic scaffolds and surgical adhesives. These products are designed to repair, reinforce or replace damaged cardiovascular and thoracic tissues during procedures such as aortic repair, heart valve surgery and vascular reconstruction.

Originally founded in 1984 under the name CryoLife, the company rebranded as Artivion in early 2022 to reflect its broader mission in cardiovascular innovation.